Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Lipari Mining (N.LML) Announces Q1-2025 Production and Sales Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Business Wire November 7, 2024

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Business Wire October 31, 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Business Wire October 10, 2024

Harrow Relaunches TRIESENCE®

Business Wire October 3, 2024

Harrow Announces Nashville Expansion

Business Wire September 25, 2024

Harrow to Present at Three Investor Conferences in September in New York

Business Wire September 3, 2024

Harrow Announces Second Quarter 2024 Financial Results

Business Wire August 7, 2024

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Business Wire July 25, 2024

Harrow to Attend 2024 ASRS Annual Meeting

Business Wire July 12, 2024

Harrow Enters into 340B Prime Vendor Program Contract with Apexus(TM) for IHEEZO® and Other Key Harrow Products

Business Wire July 9, 2024

Harrow Provides TRIESENCE® Relaunch Update

Business Wire June 20, 2024

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Business Wire June 6, 2024

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

Business Wire June 5, 2024

Harrow to Present at Two Investor Conferences in May

Business Wire May 15, 2024

Harrow Announces First Quarter 2024 Financial Results

Business Wire May 13, 2024

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

Business Wire May 13, 2024

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

Business Wire April 25, 2024

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Business Wire April 2, 2024

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

Business Wire March 19, 2024

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

Business Wire March 5, 2024